| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536725 | Vaccine | 2017 | 7 Pages |
Abstract
The results of this analysis yielded statistically significant PCV13 VE for all episodes of confirmed pneumococcal CAP (including NB/NI and culture-confirmed episodes) and for all episodes of IPD in adults aged ⩾65 years. These findings are consistent with the primary efficacy analysis. ClinicalTrials.gov identifier: NCT00744263.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Chris Webber, Michael Patton, Scott Patterson, Beate Schmoele-Thoma, Susanne M. Huijts, Marc J.M. Bonten, for the CAPiTA Study Group for the CAPiTA Study Group,